|
For most infectious diseases, chemotherapeutics are still required for disease control as vaccines are generally lacking. In addition, drug resistance has become a critical issue, which endorses the need for continuous drug research. LMPH is actively involved in the identification of new synthetic and natural lead compounds, with a particular focus on the tropical protozoal diseases Leishmaniasis, sleeping sickness, Chagas disease and malaria. Validated in vitro and in vivo test systems and drug screening technologies have been implemented at LMPH. The Drugs for Neglected Diseases Initiative (DNDi – Geneva) has access to compound libraries that have not been tested for the listed diseases. Both groups have joined expertise and know-how to achieve a more productive drug discovery.
|